男性性腺功能低下症市場規模、佔有率和成長分析：按性腺功能減退症類型、病因、治療類型、給藥途徑、診斷、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球男性性腺功能低下症市場價值為 16.5 億美元，預計到 2033 年將從 2025 年的 17.7 億美元成長至 31.4 億美元，預測期（2026-2033 年）複合年成長率為 7.4%。

全球男性性腺功能低下症市場涵蓋了診斷、荷爾蒙補充療法以及為低睪固酮水平男性提供的支持服務等商業性領域。該市場的主要驅動力是性腺功能減退症對生活品質、心血管健康和生產力的顯著影響。經皮凝膠和口服製劑等創新療法的推出加速了其應用，使這一細分市場成為醫療保健相關人員的重要領域。關鍵的成長要素包括產品創新和個人化醫療的整合，這有助於制定保險報銷策略。此外，人工智慧驅動的診斷自動化正在簡化識別和管理流程，從而實現早期干預並改善治療效果。因此，在為醫療保健系統提供經濟高效的診斷解決方案的同時，對荷爾蒙補充療法產品的需求也在不斷成長。

全球男性性腺功能低下症市場的成長要素

大眾對低睪酮水平相關症狀的認知度不斷提高，促使更多男性尋求醫療評估。這項轉變導致診斷率上升，符合荷爾蒙補充療法的患者人數增加，進而擴大了對相關藥物和醫療保健服務的需求。醫療專業人員現在對這些症狀有了更清晰的了解，這使他們能夠更有信心地開立處方。此外，患者權益倡導組織也發揮著至關重要的作用，他們提供教育資源，促進公眾就男性荷爾蒙健康問題展開公開討論。這些發展正在形成一個良性循環，提高大眾對治療的認知度和接受度，最終推動全球男性性腺功能低下症的持續成長。

全球男性性腺功能低下症市場的限制因素

睪固酮替代療法，尤其是長效注射劑和經皮製劑的高昂費用，給許多人帶來了巨大的經濟負擔，尤其是在健保覆蓋不足的地區。這種費用負擔往往導致患者需要自付大量費用，阻礙他們堅持治療方案，並促使醫療服務提供者尋求更經濟的替代方案。因此，這種對價格的敏感度阻礙了整體市場滲透，因為臨床醫生可能會優先考慮更具成本效益的處方方法。此外，除非降低價格或引入基於價值的支付模式，否則製藥公司在提高銷售量將面臨重重阻礙，最終限制了市場擴張和病患可及性。

全球男性性腺功能低下症市場趨勢

全球男性性腺功能低下症市場正呈現強勁的精準荷爾蒙療法趨勢，其特點是根據個別基因譜、症狀嚴重程度和生活方式因素量身定做個人化治療方案。臨床醫生擴大採用生物標記檢測和數位化監測技術來最佳化荷爾蒙補充療法，最大限度地減少副作用，並提高患者的依從性。這種轉變促進了內分泌學家、生育專家和技術創新者之間的合作，從而建構了整合式診療路徑，這不僅提高了病患滿意度，也為醫療機構創造了新的商機。最終，這種個人化治療模式旨在顯著改善性腺功能減退症患者的整體生活品質。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球男性性腺功能低下症市場規模：依性腺功能減退症類型分類

• 原發性（睪丸性）性腺功能減退症
• 續發性（促性腺激素依賴性）性腺功能減退症
• 混合型/合併型性腺功能減退症

全球男性性腺功能低下症市場規模：依病因分類

• 先天性性腺功能減退症
• 後天性腺功能減退症
• 與老齡化相關的遲發性性腺功能減退症
• 藥物引起的性腺功能減退
• 其他

全球男性性腺功能低下症市場規模：依治療類型分類

• 睾酮替代療法（TRT）
• 口服睾酮療法
• 注射式睾酮療法
• 經皮貼片和凝膠
• 鼻內睾酮療法
• 選擇性雌激素受體調節（SERMs）
• 促性腺激素分泌治療（hCG、hMG）
• 其他

全球男性性腺功能低下症市場規模：依給藥途徑分類

• 口服
• 肌肉內注射
• 經皮給藥
• 鼻腔
• 皮下

全球男性性腺功能低下症市場規模：依診斷分類

• 血液睪酮檢測
• 荷爾蒙檢測
• 基因檢測
• 診斷影像（腦下垂體磁振造影）
• 其他

全球男性性腺功能低下症市場規模：依最終用戶分類

• 醫院
• 專科診所
• 不孕症治療診所
• 門診部
• 居家照護環境

全球男性性腺功能低下症市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球男性性腺功能低下症市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• AbbVie Inc
• Endo International plc
• Pfizer Inc
• Eli Lilly and Company
• Bayer AG
• Merck & Co Inc
• Novartis AG
• Sanofi SA
• AstraZeneca plc
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd
• Viatris Inc
• Sandoz International GmbH
• Lupin Limited
• Cipla Limited
• Sun Pharmaceutical Industries Ltd
• Dr Reddy's Laboratories Ltd
• Hikma Pharmaceuticals PLC
• Zydus Lifesciences Limited
• Clarus Therapeutics Inc

結論與建議

Global Male Hypogonadism Market size was valued at USD 1.65 Billion in 2024 and is poised to grow from USD 1.77 Billion in 2025 to USD 3.14 Billion by 2033, growing at a CAGR of 7.4% during the forecast period (2026-2033).

The global male hypogonadism market encompasses the commercial landscape surrounding diagnostics, hormone replacement therapies, and supportive services for men suffering from low testosterone levels. This market is driven by the significant impact of hypogonadism on quality of life, cardiovascular health, and productivity. The introduction of innovative treatment options, such as transdermal gels and oral formulations, has spurred adoption and transformed this niche sector into a valuable realm for health stakeholders. Key growth factors include the integration of personalized medicine, which enhances product innovation and reimbursement strategies. Furthermore, AI-driven diagnostic automation is streamlining identification and management processes, leading to earlier interventions and better therapeutic outcomes. Consequently, this promotes demand for hormone-replacement products while providing cost-effective diagnostic solutions for healthcare systems.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Male Hypogonadism market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Male Hypogonadism Market Segments Analysis

Global male hypogonadism market is segmented by type of hypogonadism, etiology, treatment type, route of administration, diagnosis, end user, distribution channel and region. Based on type of hypogonadism, the market is segmented into Primary (Testicular) Hypogonadism, Secondary (Hypogonadotropic) Hypogonadism and Mixed/Combined Hypogonadism. Based on etiology, the market is segmented into Congenital Hypogonadism, Acquired Hypogonadism, Age-Related Late-Onset Hypogonadism, Drug-Induced Hypogonadism and Others. Based on treatment type, the market is segmented into Testosterone Replacement Therapy (TRT), Oral Testosterone Therapy, Injectable Testosterone Therapy, Transdermal Patches & Gels, Nasal Testosterone Therapy, Selective Estrogen Receptor Modulators (SERMs), Gonadotropin Therapy (hCG, hMG) and Others. Based on route of administration, the market is segmented into Oral, Intramuscular Injection, Transdermal, Nasal and Subcutaneous. Based on diagnosis, the market is segmented into Blood Testosterone Testing, Hormonal Panel, Genetic Testing, Imaging (MRI of Pituitary) and Others. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Fertility Clinics, Ambulatory Care Centers and Homecare Settings. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Male Hypogonadism Market

The rising awareness among the public regarding the symptoms associated with low testosterone levels has led to an increase in men seeking medical evaluations. This shift has resulted in higher diagnosis rates and a larger number of patients qualifying for hormone replacement therapy, consequently boosting the demand for pharmaceutical products and related healthcare services. Healthcare professionals now enjoy enhanced clarity in symptom recognition, which fosters more confident prescribing practices. Additionally, patient advocacy groups play a vital role by providing educational resources that promote open discussions about male hormonal health. This dynamic creates a positive feedback loop, promoting both awareness and treatment acceptance, ultimately supporting the ongoing growth of the global Male Hypogonadism market.

Restraints in the Global Male Hypogonadism Market

The high costs associated with testosterone replacement therapies, particularly long-acting injectables and transdermal systems, create significant financial challenges for many individuals, especially in areas lacking robust insurance coverage. This affordability issue often leads to high out-of-pocket expenses, discouraging patients from maintaining consistent treatment regimens and prompting healthcare providers to explore alternative, more budget-friendly options. Consequently, this cost sensitivity hampers overall market penetration, as clinicians may prioritize more economical prescribing practices. Additionally, pharmaceutical companies face obstacles in achieving growth in sales volume without implementing price reductions or value-based payment models, which ultimately limits market expansion and patient accessibility.

Market Trends of the Global Male Hypogonadism Market

The Global Male Hypogonadism market is witnessing a robust trend toward precision hormone therapy, characterized by personalized treatment approaches aligned with individual genetic profiles, symptom intensity, and lifestyle factors. Clinicians are increasingly adopting biomarker panels and digital monitoring technologies to optimize hormone replacement regimens, minimizing adverse effects and enhancing patient compliance. This shift is fostering collaborations among endocrinologists, fertility experts, and tech innovators, resulting in integrated care pathways that not only elevate patient satisfaction but also create new revenue opportunities for providers. Ultimately, this tailored treatment paradigm aims to significantly improve the overall quality of life for patients with hypogonadism.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Male Hypogonadism Market Size by Type of Hypogonadism & CAGR (2026-2033)

• Market Overview
• Primary (Testicular) Hypogonadism
• Secondary (Hypogonadotropic) Hypogonadism
• Mixed/Combined Hypogonadism

Global Male Hypogonadism Market Size by Etiology & CAGR (2026-2033)

• Market Overview
• Congenital Hypogonadism
• Acquired Hypogonadism
• Age-Related Late-Onset Hypogonadism
• Drug-Induced Hypogonadism
• Others

Global Male Hypogonadism Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Testosterone Replacement Therapy (TRT)
• Oral Testosterone Therapy
• Injectable Testosterone Therapy
• Transdermal Patches & Gels
• Nasal Testosterone Therapy
• Selective Estrogen Receptor Modulators (SERMs)
• Gonadotropin Therapy (hCG, hMG)
• Others

Global Male Hypogonadism Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intramuscular Injection
• Transdermal
• Nasal
• Subcutaneous

Global Male Hypogonadism Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Blood Testosterone Testing
• Hormonal Panel
• Genetic Testing
• Imaging (MRI of Pituitary)
• Others

Global Male Hypogonadism Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Fertility Clinics
• Ambulatory Care Centers
• Homecare Settings

Global Male Hypogonadism Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Male Hypogonadism Market Size & CAGR (2026-2033)

• North America (Type of Hypogonadism, Etiology, Treatment Type, Route of Administration, Diagnosis, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type of Hypogonadism, Etiology, Treatment Type, Route of Administration, Diagnosis, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type of Hypogonadism, Etiology, Treatment Type, Route of Administration, Diagnosis, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type of Hypogonadism, Etiology, Treatment Type, Route of Administration, Diagnosis, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type of Hypogonadism, Etiology, Treatment Type, Route of Administration, Diagnosis, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo International plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr Reddy's Laboratories Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clarus Therapeutics Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations